Gefitinib in the treatment of advanced non-small-cell lung cancer
M Reck - Expert Review of Anticancer Therapy, 2009 - Taylor & Francis
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
Gefitinib in the treatment of advanced non-small-cell lung cancer
M Reck - Expert Review of Anticancer Therapy, 2009 - go.gale.com
Lung cancer is the most common cancer worldwide, with approximately 1.3 million cases
recorded annually [1]. Furthermore, lung cancer is the predominant cause of cancer-related …
recorded annually [1]. Furthermore, lung cancer is the predominant cause of cancer-related …
Gefitinib in the treatment of advanced non-small-cell lung cancer
M Reck - Expert Review of Anticancer Therapy, 2009 - search.proquest.com
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
Gefitinib in the treatment of advanced non-small-cell lung cancer
M Reck - Expert review of anticancer therapy, 2009 - pubmed.ncbi.nlm.nih.gov
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
Gefitinib in the treatment of advanced non-small-cell lung cancer.
M Reck - Expert Review of Anticancer Therapy, 2009 - europepmc.org
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …